对氨基水杨酸显著降低替诺福韦暴露:体外到体内转化研究的不一致发现
本研究探讨对氨基水杨酸(PAS)对替诺福韦药代动力学的影响。体外实验显示PAS抑制OAT1/OAT3介导的替诺福韦摄取,生理药代动力学模型预测替诺福韦峰浓度升高1.26倍;但健康男性受试者的开放、随机、交叉临床试验显示,PAS钙制剂使替诺福韦Cmax和AUC0-inf的几何均值比分别降至0.33和0.29,与体外预测相反。
要点
- PAS钙制剂显著降低替诺福韦系统暴露,Cmax和AUC0-inf几何均值比分别为0.33和0.29。
- 体外OAT1/OAT3抑制及生理药代动力学模型预测替诺福韦暴露升高,与临床结果相反。
- 从体外数据预测体内药代动力学时需谨慎,尤其存在制剂相互作用等混杂因素时。
核心结论
- PAS钙制剂通过未阐明的机制显著降低替诺福韦的系统暴露,与体外预测相反。
- 从体外数据预测体内药代动力学特征需谨慎,尤其存在潜在混杂因素如制剂相互作用时。
研究设计与样本
- 体外研究使用稳定转染人OAT1和OAT3的细胞评估转运体介导的药物相互作用。
- 采用静态和生理药代动力学模型预测临床药物相互作用。
- 在健康男性韩国受试者中开展开放、随机、交叉临床试验,评估PAS钙制剂对替诺福韦二吡呋酯药代动力学的影响。
主要发现
- 体外实验显示PAS抑制OAT1和OAT3介导的替诺福韦摄取。
- 生理药代动力学模型预测替诺福韦峰浓度在合用PAS时升高1.26倍。
- 临床试验显示替诺福韦Cmax和AUC0-inf的几何均值比(90%置信区间)分别为0.33(0.28-0.38)和0.29(0.26-0.33)。
临床怎么用
- 临床合用PAS钙制剂与替诺福韦时,应警惕替诺福韦暴露显著降低可能影响疗效。
- 不应仅凭体外转运体抑制数据预测体内药代动力学相互作用,需以临床研究为准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Tenofovir and para-aminosalicylic acid (PAS) may be coprescribed to treat patients with concomitant infections of human immunodeficiency virus and Mycobacterium tuberculosis bacteria. Both drugs are known to have remarkable renal uptake transporter-mediated clearance. Owing to the lack of clinical studies on drug-drug interaction between the 2 drugs, we conducted a translational clinical study to investigate the effect of PAS on tenofovir pharmacokinetics (PK). METHODS: Initially, we studied in vitro renal uptake transporter-mediated drug-drug interactions using stably transfected cells with human organic anion transporters (OAT1 and OAT3). Later, we estimated clinical drug interactions using static and physiologically based PK modelling. Finally, we investigated the effects of PAS-calcium formulation (PAS-Ca) on tenofovir disoproxil fumarate PK in healthy male Korean subjects. RESULTS: PAS inhibited OAT1- and OAT3-mediated tenofovir uptake in vitro. The physiologically based PK drug-drug interaction model suggested a 1.26-fold increase in tenofovir peak plasma concentration when coadministered with PAS. By contrast, an open-label, randomized, crossover clinical trial evaluating the effects of PAS-Ca on tenofovir PK showed significantly altered geometric mean ratio (90% confidence intervals) of maximum plasma concentration (Cmax ) and area under the curve (AUC0-inf ) by 0.33 (0.28-0.38) and 0.29 (0.26-0.33), respectively. CONCLUSION: Our study findings suggest that the PAS-Ca formulation significantly reduced systemic exposure to tenofovir through an unexplained mechanism, which was contrary to the initial prediction. Caution should be exercised while predicting in vivo PK profiles from in vitro data, particularly when there are potential confounders such as pharmaceutical interactions.
引用
- Parvez MM, Kalkisim S, Nguyen PTT, et al. Para-aminosalicylic acid significantly reduced tenofovir exposure in human subjects: Mismatched findings from in vitro to in vivo translational research. Br J Clin Pharmacol. 2021. PMID: 34432302. doi:10.1111/bcp.15056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。